Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 3Thyroid Neoplasms 2Lung Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesonephric Gynecologic Cancer 1Melanoma 1Lymphoma 1Low-Grade Serous Ovarian Cancer 1Low Grade Serous Ovarian Cancer 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Colorectal Cancer 1Adenocarcinoma of Lung 1

Interventions

defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesonephric Gynecologic Cancer × defactinib × 90 days × Clear all
NCT05787561 2026-04-28

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Gynecologic

Mesonephric Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡